Question explored with the scientific record
How complete is Canada’s COVID-19 vaccine adverse event reporting, and can spontaneous-report systems establish deaths caused by vaccines?
The short version: Canada’s spontaneous-report system is too incomplete to establish vaccine-caused deaths, and the evidence retrieved does not contain a study that answers the question.
The evidence you gave me does not contain a single study that measures the completeness of Canada’s COVID-19 vaccine adverse event reporting or that attempts to attribute deaths to vaccines using spontaneous-report data. One paper describes underreporting in two Canadian case reports [12], but that is a description of the problem, not a measurement of the system’s completeness. Another paper shows that pooled health-data analysis across provinces could detect rare events like myocarditis faster than individual provinces can [11], but that is about signal detection speed, not about whether the spontaneous-report system captures deaths accurately. The rest of the evidence is about vaccine effectiveness, public attitudes, global distribution inequity, or adverse events in other countries. None of it addresses the question you asked.
The gap itself matters. A spontaneous-report system like Canada’s can generate hypotheses about vaccine-associated deaths, but it cannot establish causation because it has no denominator (total vaccinated), no control group (unvaccinated), and massive underreporting that is known to be biased by publicity and political factors [24, 25]. The most informative study design — vaccinated versus unvaccinated over time with adjudicated cause of death — was never run for Canada’s COVID-19 vaccines, or if it was, it was not retrieved here. Absence of evidence is not evidence of safety, but it is also not evidence of harm. The honest answer is that the evidence does not exist in the material you provided.
My call: the evidence retrieved does not answer whether Canada’s system is complete or whether it can establish vaccine-caused deaths. Confidence: not clear — the gap is in the evidence, not in my assessment.
Sources examined 32
-
Influenza Researchers Explore Real-World Data for Flu-Vaccine Evaluation and Learnings for COVID-19
Real-world data and modelling from Canadian conference posters suggest a cell-based quadrivalent influenza vaccine for ages 9–64 plus an MF59-adjuvanted trivalent vaccine for 65+ could substantially reduce influenza cases and deaths during the COVID-19 era, while revealing varia…
DOI: 10.70270/gxi09y7 -
FLAWS OF GLOBAL HEALTH GOVERNANCE AS ILLUSTRATED BY THE COVID-19 VACCINE DISTRIBUTION
A critical narrative review analyzing how flaws in global health governance and the COVAX vaccine distribution contributed to inequitable COVID-19 vaccine access, using Brazil (LMIC) and Canada (HIC) as contrasting case studies and offering policy recommendations.
DOI: 10.22409/rcj.v9i23.54728 -
Public attitudes towards COVID-19 vaccine mandates and vaccine certificates in Canada: a time series study
A time-series analysis of eight national cross-sectional surveys in Canada (Nov 2021–Mar 2022) describing how public attitudes toward COVID-19 vaccine mandates, vaccine certificates, and trust in government evolved, showing decreasing willingness to vaccinate third doses in para…
DOI: 10.1186/s13690-024-01259-8 -
Vaccinating Your Adult Diabetic Patient: What Vaccines Would You Recommend?
Diabetes markedly increases infection risk; a guideline-based vaccination strategy for adults with diabetes—covering influenza, pneumococcal, COVID-19, shingles, RSV, and routine vaccines—aims to reduce infection-related morbidity and hospitalizations.
DOI: 10.58931/cdet.2025.3242 -
Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study
In a test-negative design study in Ontario, Canada, two doses of BNT162b2 or mRNA-1273 were highly effective against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes during the period of Alpha and Beta/Gamma variant predominance, with modest waning after the second …
DOI: 10.1136/bmj.n1943 -
The potential impact of the next-generation COVID-19 mRNA-1283 vaccine in Canada
A public-health economics analysis in Canada evaluating the public health impact and cost-effectiveness of Moderna's next-generation COVID-19 vaccine mRNA-1283 compared with no vaccination and with current vaccines, finding substantial reductions in infections, hospitalizations,…
DOI: 10.1080/13696998.2025.2549630 -
81 mRNA COVID-19 vaccine safety among children and adolescents from the Canadian National Vaccine Safety Network
This document compiles three pediatric health topics in Canada: (1) safety surveillance showing mRNA COVID-19 vaccines are not associated with health events in children and adolescents, (2) usage and barriers of language interpretation services in pediatric care, and (3) a scopi…
DOI: 10.1093/pch/pxae067.080 -
Early COVID-19 and protection from Omicron in a highly vaccinated population in Ontario, Canada: a matched prospective cohort study
This study investigates the protective effects of early COVID-19 infection against subsequent Omicron infections in a highly vaccinated population in Ontario, Canada, finding a significant reduction in re-infection risk for over two years.
DOI: 10.1186/s12879-024-10331-1 -
Intention to receive a COVID-19 vaccine: results from a population-based survey in Canada
Population-based survey of adults in British Columbia, Canada, using Theory of Planned Behavior and WHO Vaccination Attitudes Scale to identify demographic and psychosocial predictors of intention to receive a COVID-19 vaccine; findings show 79.8% would vaccinate, with older age…
DOI: 10.1186/s12889-021-11098-9 -
COVID-19 Community Response Team for Toronto Homeless Services and Congregate Living Settings: an evaluation of Hospital-Community partnership through COVID-19 vaccine provision
The study evaluates a hospital–community partnership led by the COVID-19 Community Response Team at Women’s College Hospital to support Toronto shelters and congregate living settings with on-site testing and vaccine provision, using constructivist grounded theory to understand …
DOI: 10.5334/ijic.icic23194 -
Using Vaccine Safety Data to Demonstrate the Potential of Pooled Data Analysis
This study demonstrates that using pooled health services data across Canada can significantly reduce the time required to detect vaccine safety signals, particularly for rare adverse events like myocarditis and vaccine-induced immune thrombotic thrombocytopenia (VITT) following…
DOI: 10.3390/vaccines12091052 -
The Blind Spot in COVID-19 Vaccination Policies: Under-Reported Adverse Events
This article presents two case reports suggesting under-reporting of adverse events after COVID-19 mRNA vaccination, analyzes clinical and systemic factors contributing to underreporting, critiques current surveillance practices, and offers policy recommendations to improve AE r…
DOI: 10.56098/ijvtpr.v3i1.65 -
A systematic review of the evidence on the associations and safety of COVID-19 vaccination and post COVID-19 condition
This systematic review and meta-analysis evaluates whether COVID-19 vaccination before or after SARS-CoV-2 infection reduces the risk of developing post-COVID-19 condition (PCC) and whether vaccination is safe or improves PCC symptoms in people who already have PCC.
DOI: 10.1017/s0950268823001279 -
The estimated impact of decreased childhood vaccination due to COVID-19 using a dynamic transmission model of mumps in Japan
The study uses a validated SEIR dynamic transmission model to estimate the impact of decreased childhood mumps vaccination in Japan during COVID-19, projecting substantial incremental mumps cases, costs, and QALY losses under a permanent vaccination decline versus rapid recovery…
DOI: 10.1080/21645515.2020.1826799 -
How Safe Are COVID-19 Vaccines in Individuals with Immune-Mediated Inflammatory Diseases? The SUCCEED Study
The SUCCEED study investigates the safety of COVID-19 vaccines in individuals with immune-mediated inflammatory diseases, finding a low incidence of serious adverse events within 31 days post-vaccination.
DOI: 10.3390/vaccines12091027 -
Signaling COVID-19 Vaccine Adverse Events
This study investigates the masking effect in statistical signal detection methodologies for COVID-19 vaccine adverse events, revealing that certain adverse events may go undetected or delayed due to the presence of other reported vaccines.
DOI: 10.1007/s40264-022-01186-z -
Use of Big Data to Evaluate Adverse Ophthalmic Adverse Events after COVID-19 Vaccination
A retrospective cross-sectional study in Ulsan, South Korea identified 97 ophthalmic adverse events among 2,766,569 COVID-19 vaccine doses, with visual disturbance most common, rare irreversible sequelae linked to neurological, retinal, and glaucoma diagnoses, and no significant…
DOI: 10.3341/jkos.2024.65.4.267 -
Cardiovascular Adverse Events Reported from COVID-19 Vaccines: A Study Based on WHO Database
This study analyzes cardiovascular adverse events reported from COVID-19 vaccines using data from the WHO VigiBase database, highlighting significant associations with specific adverse events across different age groups and genders.
DOI: 10.2147/ijgm.s324349 -
Varicella Zoster Reactivation Following mRNA Vaccination: Two Case Reports and a Review of Cutaneous Adverse Events of COVID-19 Vaccines
Two case reports describe varicella zoster reactivation after Pfizer-BioNTech mRNA COVID-19 vaccination in an 80-year-old woman and a 57-year-old man, with a review of cutaneous adverse events.
DOI: 10.33590/emj/21-00254 -
The Incidence and Severity of Post-Vaccination Reactions after Vaccination against COVID-19
This study investigates the incidence and severity of post-vaccination reactions among healthcare workers in Poland after receiving COVID-19 vaccinations, revealing a significant underreporting of adverse reactions and a correlation between previous COVID-19 infection and the se…
DOI: 10.3390/vaccines9050502 -
COVID-19 VACCINES: TARGETS, PRE-CLINICAL STUDIES, MECHANISMS OF ACTION, ADRS, AND ROLLOUT IN INDIA – A JOURNEY SO FAR
A narrative review detailing the targets, pre-clinical studies, mechanisms of action, adverse drug reactions (ADRs), and rollout of COVID-19 vaccines in India, with emphasis on Covaxin and Covishield and the use of novel preclinical platforms.
DOI: 10.22159/ajpcr.2022.v15i12.46003 -
ADVERSE EVENTS FOLLOWED BY COVID-19 VACCINATION AMONGST HEALTHCARE PROVIDERS
54 of 101 healthcare workers vaccinated with Sinopharm COVID-19 vaccine reported adverse events, most commonly fatigue, body aches, and myalgias; one anaphylaxis occurred and rare post-vaccination COVID-19 was noted.
DOI: 10.51642/ppmj.v33i03.432 -
Adverse Events and Associated Economic Burden of COVID-19 Vaccination in Queensland, Australia: Findings from the Cross-Sectional QoVAX-Statewide Study
This study assesses the economic burden of adverse events following COVID-19 vaccination in Queensland, Australia, revealing that while most adverse events are mild and short-lived, the associated productivity costs significantly exceed direct healthcare expenses.
DOI: 10.3390/vaccines13070712 -
Reports of COVID-19 Vaccine Adverse Events in Predominantly Republican vs Democratic States
This ecological cross-sectional study using VAERS data (2020–2022 for COVID-19 vaccines with influenza vaccine data (2019–2022) as reference) finds that higher state-level Republican voting shares are associated with higher reporting of COVID-19 vaccine adverse events, including…
DOI: 10.1001/jamanetworkopen.2024.4177 -
Spontaneous Reporting to Regulatory Authorities of Suspected Adverse Drug Reactions to COVID-19 Vaccines Over Time: The Effect of Publicity
This study analyzes the spontaneous reporting of suspected adverse drug reactions (ADRs) to COVID-19 vaccines over time, particularly focusing on the impact of publicity surrounding cerebral venous and sinus thrombosis (CVST) on reporting rates.
DOI: 10.1007/s40264-021-01138-z -
A Rare Adverse Effect of the COVID-19 Vaccine on Autoimmune Encephalitis
This study reports a rare adverse effect of the COVID-19 vaccine, specifically autoimmune encephalitis associated with short-term memory loss, highlighting the need for further investigation into vaccine-related neurological complications.
DOI: 10.3390/vaccines10071114 -
COVID ‐19 and the peripheral nervous system. A 2‐year review from the pandemic to the vaccine era
This is a comprehensive narrative review (Jan 2020–Dec 2021) synthesizing COVID-19–related peripheral nervous system disorders and vaccine-associated cases, detailing GBS, cranial neuropathies, CIDP, myositis, CIM/CIP, neuralgic amyotrophy, and long-COVID PNS involvement, and co…
DOI: 10.1111/jns.12482 -
Impact of Comorbidities and Skin Diseases on Post-Vaccination Reactions: A Study on COVID-19 Vaccinations in Poland
This study investigates the impact of comorbidities and skin diseases on adverse events following COVID-19 vaccinations in a cohort from Poland, revealing that vaccination does not exacerbate chronic conditions and highlighting the need for better reporting of adverse events.
DOI: 10.3390/jcm13206173 -
Adverse Events Following COVID-19 Vaccination in Adolescents: Insights From Pharmacovigilance Study of VigiBase
This pharmacovigilance study analyzes adverse events following COVID-19 vaccination in adolescents, revealing a higher incidence of myocarditis/pericarditis and multisystem inflammatory syndrome compared to other vaccines, while finding no significant increase in anaphylaxis, Gu…
DOI: 10.3346/jkms.2024.39.e76 -
Adverse drug reactions from two COVID-19 vaccines reported in Saudi Arabia
This study investigates the adverse drug reactions (ADRs) reported from two COVID-19 vaccines, tozinameran and ChAdOx1, among citizens and residents in Saudi Arabia, revealing significant differences in the nature and onset of ADRs between the two vaccines.
DOI: 10.1007/s40267-022-00893-y -
COVID-19 Vaccination-Associated Spontaneous Heparin-Induced Thrombocytopenia Syndrome
A 51-year-old man developed severe transient thrombocytopenia with positive heparin-PF4 antibodies after a Pfizer-BioNTech COVID-19 booster (following Moderna primary series) without proximate heparin exposure, consistent with spontaneous heparin-induced thrombocytopenia, and re…
DOI: 10.46347/jmsh.v9i2.22.525 -
Computed Tomography Imaging of COVID-19 Vaccination–related Axillary Lymphadenopathy: Updated Review of Literature
This systematic review synthesizes evidence that COVID-19 vaccination frequently causes ipsilateral axillary lymphadenopathy on chest CT (9-53% incidence) that mimics metastasis but resolves spontaneously, creating diagnostic challenges in cancer patients undergoing surveillance…
DOI: 10.32388/9qstn6